# National Medical Products Administration

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/national-medical-products-administration
Canonical HTML page: https://getbiobrief.com/entity/national-medical-products-administration

## Timeline

- **2026-06-22**: NMPA releases 2025 report — China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-02**: Cost advantages quantified — At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
- **2026-01**: Regulatory Designations — HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
- **2026**: Trial Expansion — Continued enrollment across global multicenter sites for the 24-week study.
- **2025-Q4**: Phase II Completion — Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
- **2025**: Record trial count achieved — 5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
- **2020**: Pre-surge baseline — Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).

## Recent coverage (2 stories)

### China’s 5,215 Clinical Trials in 2025 Double Since 2020; Cancer Drugs Lead Surge
2026-06-24 10:39:00 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Full story: https://getbiobrief.com/story/china-5215-clinical-trials-2025-oncology-lead

### Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
2026-03-25 12:13:15 · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Full story: https://getbiobrief.com/story/hope-medicine-hmi-115-phase-iii-endometriosis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.